Get the Daily Brief
Latest Biotech News
IL‑12 nanoparticles plus checkpoint inhibitors wipe out ovarian metastases in mice
MIT and collaborators reported in Nature Materials that polymer‑coated nanoparticles engineered to deliver IL‑12 directly to ovarian tumor sites produced durable antitumor immunity when combined...
Patent cliff looms—Biopharma M&A surges as companies chase new revenues
Industry analysis found approximately $230 billion in annual sales tied to top blockbusters facing patent expirations through 2029, triggering accelerated M&A and portfolio reshaping across big...
Engineered Cas9 and Baby KJ pathway: lab fixes meet regulatory playbook
A University of California Berkeley team reported a protein engineering strategy that increases Cas9 nuclear import by inserting additional nuclear localization signals into surface loops,...
Myeloid and tumor genomic mechanisms map immunotherapy resistance
Dana‑Farber investigators identified interferon‑gamma signaling within tumor‑associated myeloid cells as a driver of resistance to immune checkpoint inhibitors in advanced renal cell carcinoma....
AI sharpens discovery—binding affinity models and scaled virtual cells
MIT and Recursion’s Boltz‑2 model demonstrated rapid, accurate binding‑affinity predictions, reporting affinity calculations in seconds and matching top performance in recent CASP benchmarking....
Pfizer sues to enforce Metsera buyout — court fight ignites
Pfizer sued Metsera and Novo Nordisk in Delaware’s Court of Chancery to block Metsera from terminating a September buyout agreement, alleging Novo’s rival bid breaches the merger pact and...
Moderna’s post‑Covid pivot falters — layoffs, contract losses and valuation collapse
A detailed report chronicles Moderna’s rapid reversal from pandemic-era hero to a company under heavy financial and strategic pressure. Executives have cut costs and reorganized after...
FDA halts Intellia’s CRISPR trials after liver safety signals
The FDA imposed a clinical hold on Intellia’s Phase 3 trials of nexiguran ziclumeran (nex‑z), a CRISPR‑based in vivo gene‑editing therapy for transthyretin amyloidosis, after investigators...
Gene therapy milestone: ADA‑SCID ‘cure’ shows durable success
A joint UCL–UCLA research program reported long‑term, disease‑modifying results for an ADA‑SCID gene therapy, with a multi‑year follow‑up showing roughly 95% success and no serious safety signals....
Human kidney organoids scaled and grafted into porcine kidneys
Researchers published a pair of advances: a reproducible, scalable protocol to produce thousands of human kidney organoids and the first successful integration of those organoids into perfused...
Thermo Fisher moves on Clario — $8.88B buy to tighten clinical data stack
Thermo Fisher Scientific agreed to acquire Clario Holdings for $8.88 billion in cash, aiming to integrate Clario’s endpoint data and patient‑centric clinical trial technology into Thermo’s...
Cas9 delivery and Baby KJ dossier reshape bespoke gene‑therapy pathway
A UC Berkeley team reported a protein‑engineering strategy that inserts additional nuclear localization signals into internal Cas9 loops to substantially increase nuclear import and gene‑editing...
AI and compute scale speed drug discovery and virtual cell modeling
New physics‑grounded AI models and collaborations are accelerating early drug discovery and biological simulation. Researchers showcased Boltz‑2 and related large quantitative models that predict...
Nanoparticles reinvigorate ovarian cancer immunotherapy
Two independent preclinical programs reported that nanoparticle platforms can concentrate IL‑12 in ovarian tumors and boost responses to checkpoint blockade. MIT and collaborators described...
Bird‑flu spillovers push phage therapy and antiviral innovation
Rising HPAI (H5N1) spillovers into livestock and sporadic human cases have refocused research on complementary countermeasures, including bacteriophage therapeutics to treat secondary bacterial...
Pfizer sues to block Novo’s Metsera bid—Delaware court showdown
Pfizer filed suit in Delaware’s Court of Chancery against Metsera and Novo Nordisk to stop Novo’s unsolicited takeover approach and enforce a September buyout agreement, the companies announced...
FDA halts Intellia’s CRISPR Phase 3 trials after liver safety signals
The U.S. Food and Drug Administration placed a clinical hold on Intellia’s two Phase 3 studies of its in vivo CRISPR editing therapy nexiguran ziclumeran (nex‑z) for transthyretin amyloidosis...
UCL–UCLA gene therapy for ADA‑SCID hits curative milestone in long follow‑up
A joint UCL–UCLA clinical program reported multi‑year data showing their lentiviral gene therapy for ADA‑SCID produced immune reconstitution in treated children with a roughly 95% success rate and...
Baby KJ model: FDA guidance and one‑off CRISPR therapies move toward scalability
Researchers who created the bespoke CRISPR treatment for Baby KJ published their FDA interactions and described plans to translate the single‑patient emergency program into a replicable regulatory...
IL‑12 nanoparticles reverse ovarian tumor immune suppression in mice
MIT researchers engineered polymer‑coated nanoparticles that deliver IL‑12 directly into ovarian tumors and dramatically improved responses to immune checkpoint inhibitors in preclinical models....